Last reviewed · How we verify

Fluticasone/Salmeterol Discus 250/50 µg — Competitive Intelligence Brief

Fluticasone/Salmeterol Discus 250/50 µg (Fluticasone/Salmeterol Discus 250/50 µg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist combination. Area: Respiratory.

phase 3 Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Fluticasone/Salmeterol Discus 250/50 µg (Fluticasone/Salmeterol Discus 250/50 µg) — AstraZeneca. Fluticasone propionate (inhaled corticosteroid) reduces airway inflammation while salmeterol (long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Fluticasone/Salmeterol Discus 250/50 µg TARGET Fluticasone/Salmeterol Discus 250/50 µg AstraZeneca phase 3 Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
fluticasone/salmeterol DISKUS 250/50 fluticasone/salmeterol DISKUS 250/50 Allergy & Asthma Medical Group & Research Center marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
SFC SFC GlaxoSmithKline marketed Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (fluticasone); Beta-2 adrenergic receptor (salmeterol)
Fluticasone/Salmeterol Diskus Fluticasone/Salmeterol Diskus Johns Hopkins University marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Symbicort® forte Turbohaler® Symbicort® forte Turbohaler® University Hospital, Antwerp marketed Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)
Fluticasone/Salmeterol high dose Fluticasone/Salmeterol high dose Far Eastern Memorial Hospital marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Salmeterol Fluticasone Salmeterol Fluticasone Università degli Studi di Brescia marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist combination class)

  1. GlaxoSmithKline · 14 drugs in this class
  2. Pearl Therapeutics, Inc. · 5 drugs in this class
  3. AstraZeneca · 4 drugs in this class
  4. Research in Real-Life Ltd · 3 drugs in this class
  5. Chiesi Farmaceutici S.p.A. · 2 drugs in this class
  6. Istituto per la Ricerca e l'Innovazione Biomedica · 1 drug in this class
  7. Johns Hopkins University · 1 drug in this class
  8. National Jewish Health · 1 drug in this class
  9. SkyePharma AG · 1 drug in this class
  10. University Medical Center Groningen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluticasone/Salmeterol Discus 250/50 µg — Competitive Intelligence Brief. https://druglandscape.com/ci/fluticasone-salmeterol-discus-250-50-g. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: